VYYRF - Voyageur Pharmaceuticals Provides Update on PEA Progress & Takes a Major Step Towards Production Start Up
(TheNewswire)
Calgary, Alberta - TheNewswire - December 6 ,2021 - VoyageurPharmaceuticals Ltd. (TSXV:VM) ( OTC : VYYRF) (the "Company"or "Voyageur") has a preliminaryeconomic assessment (PEA) on its Frances Creek project pending withSGS Canada, who have stated the first draft will be completed by midDecember. There have been delays outside of management's control.Building out the mining operation and product manufacturing representsthe second phase of Voyageur’s plan.
Voyageur is working with its manufacturing partner;Alberta Veterinarian Laboratories / Solvet and has completed its firsttest batch of barium contrast media. Voyageur is working on clinicaltesting of this first batch to ensure quality and performance.Voyageur's goal is to complete testing for the Canadian product launchby February followed by a marketing campaign for sales into theCanadian radiology market.
Voyageur is focused in the near term on developing asuite of Computed Tomography products with the lead product being theSmoothX barium contrast brand. The FDA is currently working withVoyageur on creating a new regulatory pathway, to create a deviceregistration. Voyageur expects to submit its device application assoon as the new guidelines are approved by the FDA. Voyageur willprovide updates on FDA progress, as each milestone is achieved.
Voyageur plans to penetrate the US market uponcompletion of FDA device licensing, that is estimated to be completedin 2022. Voyageur is concurrently creating a drug dossier for foreignmarkets (EU/Uk/Japan) that regulate barium sulfate as a drug.Voyageur’s objective is to have regulatory filings for SmoothX intothe UK, EU and Japan, and initiate the penetration into the globalmarkets by end of 2022 to 2023.
Concurrently Voyageur is proceeding with multiple batchtesting of its product to meet FDA and EU regulatory standards forlicensing requirements. This work is directly tied into the FDA and EUregulatory approval process.
About Voyageur
Voyageur is a Canadian public company listed on theTSXV under the trading symbol VM. Voyageur is focused on thedevelopment of barite and iodine Active Pharmaceutical Ingredients(“API”) and high-performance cost-effective imaging contrastagents for the medical radiology marketplace. Voyageur’s goal is toinitially generate positive cash flow from operations using thirdparty GMP pharmaceutical manufacturers in Canada and internationally.Ultimately, Voyageur has plans to build all the requiredinfrastructure to become 100% self-sufficient with all manufacturing.Voyageur owns a 100% interest in three barium sulphate (barite)projects including the Frances Creek property, suitable in grade forthe pharmaceutical barite marketplace, with interests in a high-gradeiodine, lithium & bromine brine project located in Utah,USA.
Voyageur is moving forward with its business plan ofbecoming the only fully integrated company in the radiology medicalfield, by controlling all primary input costs under the motto of:"From the Earth to the Bottle".
For Further MediaInformation or to set up an interview, please contact:
BrentWillis
President &CEO
Ebrent@vpharma.ca
Ron Love
CFO
T403.818.6086
E ronl@vpharma.ca
Forward LookingInformation
This news releasemay contain certain forward-looking information and statements,including without limitation, statements pertaining to: the timing ofthe drafts and final PEA; the timing and success of the clinicaltesting of the first batch of barium contrast media and the subsequentmarketing campaign, the timing and success of the registration withthe FDA as a device or otherwise, the timing and success ofpenetrating the US and other markets, the timing and success of theCompany's products meeting various regulatory standards, and theCompany's long term plans, including with respect to becoming 100%self-sufficient with all manufacturing. All statements includedherein, other than statements of historical fact, are forward-lookinginformation and such information involves various risks anduncertainties. There can be no assurance that such information willprove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR website atwww.sedar.com. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.
ReaderAdvisory
Neither the TSXVnor its Regulation Services Provider (as that term is defined in thepolicies of the TSXV) accepts responsibility for the adequacy oraccuracy of this news release.
Copyright (c) 2021 TheNewswire - All rights reserved.